Viking Therapeutics, Inc.(VKTX)今日盘中大涨5.10%,引发了市场广泛关注。公司旗下新型减肥药物VK2735的早期临床试验数据将于今年11月初公布,预期将为公司的新药研发工作带来利好消息。
据悉,VK2735是一种肽类GLP-1/GIP双受体激动剂,目前已完成2期临床试验。根据初步结果显示,一周一次剂量为15毫克的VK2735皮下注射在肥胖症患者中取得显著疗效,患者体重平均减轻14.7%,相当于29.2磅。VK2735口服剂在28天内也能使受试者体重下降5.3%。该药物在试验中展现出良好的安全性和耐受性,为后续3期临床试验奠定了基础。
这一积极的临床进展令Viking Therapeutics的股价一度触及99.41美元的历史新高。投资界普遍认为,VK2735有望成为突破性的减肥新药,如果最终获批上市,必将极大提振Viking Therapeutics的业绩和市值水平。就在昨日,摩根大通给予该股"增持"评级,目标价为80美元,并将其列入积极观察名单,进一步助推了Viking Therapeutics股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.